Big data analytics for MerTK genomics reveals its double-edged sword functions in human diseases

Shijie Liu, Jinzi Wu, Daixuan Yang, Jianliang Xu, Hang Shi, Bingzhong Xue, Zufeng DingRedox 2024 · DOI

TL;DR

This study leverages big data analytics on human genomic and transcriptomic data to reveal the complex, dual role of the MerTK receptor in human health and disease. The findings suggest MerTK can be a therapeutic target, but its modulation strategy (inhibition vs. restoration) must be tailored to specific diseases and even sex.

What Problem Does This Paper Address?

The MerTK receptor is known to be crucial for clearing apoptotic cells (efferocytosis), a process vital for maintaining tissue homeostasis and resolving inflammation. Dysregulation of MerTK has been implicated in various diseases, including cardiovascular issues, cancer, and neurological disorders. However, the precise expression patterns of MerTK across a broad spectrum of human cells, tissues, and diseases, and how these patterns differ between sexes, remained largely uncharacterized. This paper aims to fill this gap by using large-scale genomic data to map MerTK's expression landscape and uncover its context-dependent functions, thereby informing potential therapeutic strategies.

Methods

The researchers employed a "big data analytics" approach, primarily utilizing RNA-sequencing (RNA-seq) and single-cell RNA-sequencing (scRNA-seq) data. They analyzed a substantial dataset of approximately 42,700 human samples, covering cells, tissues, and various disease states. The core analytical tools included:

  • QIAGEN Ingenuity Pathway Analysis (IPA): Used for analyzing gene expression data, identifying biological functions, and mapping molecular networks. This tool helps to understand the downstream effects of MerTK expression changes.
  • BioGPS: A public database used to access and analyze MerTK gene expression profiles in normal human cells and tissues.
  • GraphPad Prism: Standard software for data analysis, graphing, and presentation.

The expression of MerTK was quantified using Log2 (FPKM + 0.1), a normalized measure of gene expression. The data were meticulously sorted by cell type, tissue type, disease, and sex to identify specific patterns and differences.

Datasets

The study primarily utilized publicly available datasets:

  • NCBI Gene Expression Omnibus (GEO): The source for the vast majority of RNA-seq and scRNA-seq data.
  • QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN OmicSoft Land Explorer: Provided access to curated datasets and analytical tools for gene expression analysis.
  • BioGPS: Used for accessing and analyzing MerTK transcript expression in human tissues.

No new benchmark datasets were introduced; instead, the study focused on comprehensive analysis of existing large-scale data.

Key Insights and Ideas

  • MerTK's "Double-Edged Sword": The most striking insight is MerTK's dual nature. It's crucial for clearing apoptotic cells and resolving inflammation, which is beneficial in conditions like atherosclerosis. However, in cancer, its role in promoting efferocytosis can inadvertently suppress anti-tumor immunity, making it a target for inhibition.
  • Sex Differences Matter: The study uncovered significant sex-specific differences in MerTK expression in several tissues, including artificial tissues, blood vessels, the gastrointestinal system, hematopoietic/lymphoid system, and muscle. This highlights the need to consider sex as a critical factor in MerTK-targeted therapies.
  • Cell-Type Specificity: MerTK expression is not uniform. It's highly expressed in immune cells like macrophages and monocytes, but also found in progenitor cells, certain T and B cells (especially in tumor microenvironments), and endothelial cells. This broad expression pattern underscores its multifaceted roles.
  • Tissue-Specific Roles in Disease: MerTK expression is significantly altered in a wide array of human diseases, from cardiovascular and neurological disorders to cancer and aging. The specific direction of change (up or down) often dictates its functional impact.

Key Results

  • Broad Expression: MerTK is widely expressed in human macrophages, monocytes, progenitor cells, T and B cells, and endothelial cells. It's also highly expressed in various human tissues, including plaque, blood vessels, heart, liver, and the central nervous system.
  • Disease-Associated Alterations: MerTK expression is significantly altered in numerous diseases, including cardiovascular diseases, cancer, and brain disorders. For instance, it's lower in myocardial infarction and intracranial aneurysms but higher in breast adenocarcinoma.
  • Sex-Specific Expression: Significant differences in MerTK expression between males and females were observed in several tissues, suggesting sex-specific therapeutic considerations.
  • Proteomics Validation: Proteomic analysis in human aortic endothelial cells (HAECs) confirmed MerTK's role in efferocytosis and revealed that MerTK knockout can inhibit pathways related to autophagy, immune response, and promote apoptosis, while also predicting premature aging, kidney, and heart failure.

Limitations and Future Work

  • Cross-Validation Needed: The authors acknowledge that their findings, based on big data analytics, require cross-validation through experimental methods like q-PCR, Western blotting, and immunostaining.
  • Mechanistic Elucidation: While the study identifies expression patterns and predicts functions, further investigation into the precise cellular and molecular mechanisms of MerTK is needed, potentially using CRISPR/Cas9 technology or animal models.
  • Disease Severity and Type: It remains unclear whether MerTK expression changes are controlled by disease type or severity, necessitating more clinical studies with identical disease profiles.
  • Translational Outlook: The study provides a strong rationale for developing MerTK-targeted therapeutics, but clinical trials are essential to confirm their safety and efficacy. The authors suggest that MerTK inhibition could be a strategy for cancer therapy, while restoration might benefit conditions like atherosclerosis.

Summary updated

Abstract

Our big data analytics suggest that MerTK may be a promising therapeutic target, but how it should be modulated depends on the disease types and sex differences. For example, MerTK inhibition emerges as a new strategy for cancer therapy due to it counteracts effect on anti-tumor immunity, while MerTK restoration represents a promising treatment for atherosclerosis and myocardial infarction as MerTK is cleaved in these disease conditions.
BibTeX
@inproceedings{liu2024big,
  author = {Shijie Liu and Jinzi Wu and Daixuan Yang and Jianliang Xu and Hang Shi and Bingzhong Xue and Zufeng Ding},
  title = {{Big data analytics for MerTK genomics reveals its double-edged sword functions in human diseases}},
  booktitle = {Redox},
  year = {2024},
  doi = {10.1016/j.redox.2024.103061},
}
Figure